Living definition
What is Verve Therapeutics VERVE-102 In Vivo Base Editing (PCSK9)?
Synthetic Biology & Gene Editing Bio, Health & Neuro
- As of
- 2026-08-20
- Revision
- 2026-08-17.1
- Method
- v1.3.0
Definition
The term, in context
AI-assisted draft · approved dataset
VERVE-102 is an experimental in vivo gene-editing therapy from Verve Therapeutics that uses lipid nanoparticles to deliver a base-editing system directly into the liver, permanently switching off the PCSK9 gene to durably lower a patient's LDL cholesterol with a single treatment rather than continuous drug dosing.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-08-20, verified readiness is 24 (claimed 35, reported 32, gap 11) — Growing evidence strength; current signals suggest Track; not yet.
The readiness fact belongs to the canonical Readiness Verdict for Verve Therapeutics VERVE-102 In Vivo Base Editing (PCSK9).
Dataset approval
Human editorial release
pragma.vision editorial — standing authorization (operator dev@soft.house, 2026-07-17)
- Dataset
- 2026-08-17.1
- Hash
- sha256:0c37108a182f510fc8cf4d1dfc3a30339f2b59e62654201edea2f530a268707e
- Approved
- 2026-08-17